________________________________________________________________________________________________________________________________

(C) Private 2008 - Hugh IlyineStem Cells - Failings and Deliveries

September 2009. Failings of stem cell applications raise questions on deliverables. How does venture capital respond? Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, as well as interests of venture capital, and evaluates the balance. Still full of insights many years after the first publication.

 

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)
3 pages, no adverts

Article free of advertisement - 3 pages
- answers how a stem cell is identified in practice; commercialisation issues

Full Company License enquire here

Back to section

Related Editorial Articles

Make or Break Drug Discovery and Biopharma of Merck Life Science

Leroy Hood: Thinking Further about Stem Cells

Patient-centered Precision Care
Michael Christman, President of the Coriell Institute for Medical Research at Camden, New Jersey talks about some tricky issues of turning research on genotyping into healthcare routines

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

The Myriad Way
Peter D Meldrum, CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Novartis: Preparing for Another Level of Innovation
Mark Fishman, President of the Novartis Institutes for BioMedical Research and Member of the Executive Committee of Novartis, comments his company’s strategy in the stem cells field including technology acquisitions in the field

Patenting Stem Cells – Behind the Front StagesThe patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems